2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

influenza infection model

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145586
    Onradivir

    ZSP1273

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection .
    Onradivir
  • HY-168034
    diABZI-4

    		STING Integrin NF-κB SARS-CoV Infection Inflammation/Immunology
    diABZI-4 is a STING activator and broad-spectrum antiviral agent with immunostimulatory activity. diABZI-4 triggers the TBK1-IRF3 and NF-κB signaling cascades by inducing STING oligomerization, thereby promoting the production of type I/III interferons and various proinflammatory cytokines. diABZI-4 exhibits broad-spectrum antiviral activity and effectively inhibits the replication of influenza A virus, SARS-CoV-2, herpes simplex virus, and other viruses. diABZI-4 also activates lymphocytes and macrophages to provide significant pre- and post-exposure protection in viral disease models. diABZI-4 can be used to study COVID-19, respiratory viral infections, and related immunopathological mechanisms .
    diABZI-4
  • HY-103363
    SB-328437
    3 Publications Verification

    		 CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437
  • HY-134090
    9-Methylstreptimidone

    Antibiotic TS 885; NSC 248958

    		 Bacterial VSV Infection
    9-Methylstreptimidone is a microbial metabolite originally isolated from Streptomyces sp. S-885 that has antifungal and antiviral activities. It is active against several fungi, including S. sake, S. fragilis, R. rubra, T. rubra, and C. albidus (MICs=4-20 μg/mL) and has antiviral activity against poliovirus, vesicular stomatitis virus (VSV), and Newcastle disease virus (NDV) in vitro (MIC=0.02 μg/mL for all). 9-Methylstreptimidone increases survival in mouse models of infection with influenza A2 (H2N2) or C. albicans when administered prior to infection.
    9-Methylstreptimidone
  • HY-177332
    SLC-391

    		TAM Receptor SARS-CoV Akt Infection Cancer
    SLC-391 is an orally active AXL kinase inhibitor with an IC50 of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer .
    SLC-391
  • HY-145586A
    Onradivir monohydrate

    ZSP1273 monohydrate

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) monohydrate is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir monohydrate inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir monohydrate maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir monohydrate can be used for the research of influenza A virus infection .
    Onradivir monohydrate
  • HY-162680
    OSC-GCDI(P)

    		Influenza Virus Infection
    OSC-GCDI(P) is a broad-spectrum orally active anti-influenza virus agent that exhibits significant inhibitory effects against both wild-type and Oseltamivir (HY-13317) resistant (H275Y) influenza virus strains in mouse infection models. OSC-GCDI(P) is capable of preventing not only wild-type influenza viruses but also OS-resistant variants with NA(H275Y) .
    OSC-GCDI(P)
  • HY-155731
    Antiviral agent 35

    		Influenza Virus Infection
    Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC50 >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC50 of 2.28 μM .
    Antiviral agent 35
  • HY-182895
    Influenza A virus-IN-19

    		Influenza Virus Infection
    Influenza A virus-IN-19 (Compound (S)-63) is an orally active, selective Influenza A virus inhibitor with an EC50 of 0.44 μM. Influenza A virus-IN-19 exhibits moderate binding affinity to Hemagglutinin, with a Kd of 5.66 μM. Influenza A virus-IN-19 inhibits trypsin-mediated cleavage of HA0, blocks the early viral entry process, and suppresses the replication of Influenza A virus. Influenza A virus-IN-19 improves the survival rate of mice in lethal influenza models. Influenza A virus-IN-19 can be used in studies related to Influenza A virus infection .
    Influenza A virus-IN-19
  • HY-103363R
    SB-328437 (Standard)

    		Reference Standards CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 (Standard) is the analytical standard of SB-328437 (HY-103363). This product is intended for research and analytical applications. SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437 (Standard)
  • HY-183313
    IAV-IN-5

    		Influenza Virus Apoptosis NF-κB Interleukin Related NO Synthase Toll-like Receptor (TLR) Infection
    IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection .
    IAV-IN-5
  • HY-181691
    JAK2-IN-20

    		JAK Influenza Virus Infection
    JAK2-IN-20 is an orally active dual inhibitor targeting JAK2 kinase (IC50=49.17 nM) and influenza A virus PB2 protein (IC50=3.337 μM, Kd=2.82 μM). JAK2-IN-20 effectively blocks the JAK/STAT signaling pathway by reducing the phosphorylation levels of STAT1 and STAT3, thereby inhibiting viral replication and downregulating the expression of viral NP and PB2 proteins. In addition, JAK2-IN-20 significantly inhibits the mRNA expression of key inflammatory cytokines such as IL-6, TNF-α and IFN-β in inflammation and influenza infection models. JAK2-IN-20 serves as an important tool molecule for the study of influenza A virus infection and related pathologies .
    JAK2-IN-20

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: